Table 2. Antiviral Potencies of Carboxamides 5a–5e in Cells Infected with HIV-1 Constructs Containing WT or Mutant IN.
EC50 (FC, IN mutantsc) |
||||||
---|---|---|---|---|---|---|
compd | CC50 (μM)a | EC50 (nM, WT)b | Y143R | N155H | G140S/Q148H | SId |
5a | >250 | 372 ± 63 | 1× | N/Ae | N/Ae | >672 |
5b | >250 | 171 ± 57 | 3× | N/Ae | N/Ae | >1462 |
5c | >250 | 123 ± 21 | 3× | N/Ae | N/Ae | >2033 |
5d | >250 | 6.3 ± 2.4 | 16× | 67× | N/Ae | >39683 |
5e | >250 | 14 ± 1.9 | 2× | 8× | 32× | >17857 |
Cytotoxic concentration resulting in 50% reduction in the level of ATP in human osteosarcoma (HOS) cells.
Values obtained from cells infected with lentiviral vector harboring WT IN.
Cells were infected with viral constructs carrying IN mutations and indicated values correspond to the fold-change (FC) in EC50 relative to WT.
Selectivity index calculated as the ratio of CC50 to EC50.
Not available.